Molecular Biology Enzymes, Kits & Reagents Market Size & Share Analysis, 2030

Name: Molecular Biology Enzymes, Kits & Reagents Market Size & Share Analysis, 2030
Creator: Mordor Intelligence
License: https://www.mordorintelligence.com/privacy-policy

Molecular Biology Enzymes, Kits And Reagents Market Size and Share

Market Overview

Study Period	2019 - 2030
Market Size (2025)	USD 13.68 Billion
Market Size (2030)	USD 22.53 Billion
Growth Rate (2025 - 2030)	10.50% CAGR
Fastest Growing Market	Asia Pacific
Largest Market	North America
Market Concentration	Medium
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Molecular Biology Enzymes, Kits And Reagents Market (2025 - 2030) — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Molecular Biology Enzymes, Kits And Reagents Market Analysis by Mordor Intelligence

The molecular biology enzymes, kits & reagents market is valued at USD 13.68 billion in 2025 and is forecast to reach USD 22.53 billion by 2030, reflecting a 10.5% CAGR. Strong momentum comes from next-generation sequencing platform upgrades, growing clinical adoption of single-cell multi-omics assays, and the shift toward field-deployable, lyophilized diagnostics. Ultra-high-fidelity enzyme innovations are raising analytical precision, enabling detection of rare mutations and supporting CRISPR-based therapeutic pipelines. At the same time, sustained federal R&D spending in North America and Europe, coupled with intensified life-science investment in Asia-Pacific, is enlarging the customer base for high-value consumables. Competitive rivalry is intensifying as large suppliers pursue strategic acquisitions to integrate sample preparation, amplification, detection, and data-analysis capabilities, while smaller specialists stake out opportunities in sustainable consumables and machine-learning-guided enzyme engineering.

Key Report Takeaways

By product category, kits & reagents led with 65.52% revenue share in 2024, while enzymes are advancing at a 12.25% CAGR through 2030.
By application, PCR retained 45.53% of the molecular biology enzymes, kits & reagents market share in 2024, whereas next-generation sequencing is projected to expand at 16.53% CAGR to 2030.
By end-user, hospitals & diagnostic centers commanded 45.82% of the molecular biology enzymes, kits & reagents market size in 2024; contract research & manufacturing organizations post the quickest growth at 13.26% CAGR.
By form, liquid products held 58.82% revenue share in 2024; lyophilized formats are rising at 14.62% CAGR as cold-chain-free diagnostics gain traction.
By geography, North America dominated with 38.82% market share in 2024, while Asia-Pacific is forecast to grow at 11.32% CAGR through 2030.

Global Molecular Biology Enzymes, Kits And Reagents Market Trends and Insights

Drivers Impact Analysis

Driver	(~) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Rapid Advances In NGS, qPCR & dPCR Platforms	+2.3%	Global, with early adoption in North America and EU	Medium term (2-4 years)
Rising Incidence Of Infectious Diseases & Genetic Disorders	+2.1%	Global, with concentrated impact in APAC and MEA	Medium term (2-4 years)
Growing Adoption Of Precision-Medicine Diagnostics	+1.9%	North America & EU, expanding to APAC urban centers	Long term (≥ 4 years)
Expanding Life-Science R&D Budgets	+1.8%	North America & EU core, spillover to APAC	Short term (≤ 2 years)
Ultra-High-Fidelity Enzymes Enabling Single-Cell Multi-Omics	+1.2%	Global research hubs, concentrated in North America and EU	Long term (≥ 4 years)
Field-Deployable Lyophilized Kits Reduce Cold-Chain Costs	+0.9%	Global, with highest impact in resource-limited settings	Medium term (2-4 years)

Source: Mordor Intelligence

Rising Incidence of Infectious Diseases & Genetic Disorders

COVID-19 highlighted the value of rapid nucleic-acid testing, accelerating demand for portable molecular platforms such as a lyophilized LAMP-based Dragonfly system that achieved 96.1% sensitivity for mpox detection^{[1]Jesús Rodríguez-Manzano, “Portable molecular diagnostic platform for rapid point-of-care detection of mpox and other diseases,” Nature Communications, nature.com}. Health systems now view early molecular surveillance as essential for outbreak containment and cost control. Expanded newborn genetic-disorder screening and population-level carrier testing require enzymes with extremely low error rates to spot rare variants. CRISPR-based detection chemistries and microfluidic cartridges are entering frontline laboratories, enlarging the addressable market for high-value reagents.

Expanding Life-Science R&D Budgets

A 2025 survey showed overall academic research budgets rising 4%, even as some capital-equipment lines stayed flat, signaling a tilt toward high-turnover consumables. Contract research organizations increasingly win bulk-supply agreements, encouraging vendors to offer customized master mixes and sustainably packaged kits.

Rapid Advances in NGS, qPCR & dPCR Platforms

Third-generation sequencers such as Oxford Nanopore and PacBio reduce amplification steps, yet drive demand for specialty polymerases tolerant of long reads and modified bases. Enzymatic DNA synthesis has achieved 1,005-mer oligonucleotides at 99.9% yield, cutting hazardous waste relative to phosphoramidite chemistry. Takara Bio’s SmartChip ND system performs 5,184 qPCR reactions in under 30 minutes, underscoring the need for heat-stable enzymes and pre-aliquoted reagent plates. Machine-learning-guided cell-free expression accelerates screening of 10 million polymerase mutants per day, shrinking development cycles.

Growing Adoption of Precision-Medicine Diagnostics

Genomic profiling is moving beyond oncology into neurology and immunology. The myeloMATCH trial employs a one-day NGS workflow to place acute myeloid leukemia patients into matched studies, illustrating clinical demand for rapid library-prep kits. Companion-diagnostic partnerships tie reagent sales to drug launches, yet U.S. MolDX coverage policies still require exhaustive clinical-utility data, delaying revenue recognition^{[2]Centers for Medicare & Medicaid Services, “Billing and Coding: Genetic Testing for Oncology,” cms.gov}.

Restraints Impact Analysis

Restraint	(~) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
High Cost & Limited Reimbursement For Genetic Testing	-1.6%	Global, most pronounced in North America and EU	Short term (≤ 2 years)
Fragile Supply Chain For Specialty Recombinant Reagents	-1.1%	Global, with acute impact in APAC manufacturing	Medium term (2-4 years)
Complex IP & Licensing Landscape For Enzyme Patents	-0.8%	Global, concentrated in innovation hubs	Long term (≥ 4 years)
Sustainability Pressure On Single-Use Kit Plastics	-0.7%	EU and North America leading, expanding globally	Long term (≥ 4 years)

Source: Mordor Intelligence

High Cost & Limited Reimbursement For Genetic Testing

Medicare’s MolDX program uses stringent clinical-utility thresholds, leaving many novel assays uncovered or reimbursed below cost. Private insurers now demand real-world evidence, adding time and expense to test launches. Smaller labs struggle to fund multi-site trials, constraining innovation until payers harmonize evidence standards.

Complex IP & Licensing Landscape for Enzyme Patents

More than 11,000 CRISPR-related patents create a thicket that newcomers must navigate^{[3]World Intellectual Property Organization, “CRISPR-Cas: Navigating the Patent Landscape to Explore Boundless Applications,” wipo.int}. Ongoing UC–Broad disputes over Cas9 raise licensing uncertainties that ripple across polymerase and ligase portfolios. Royalty stacking inflates bill-of-materials costs and can deter investment in next-generation editing enzymes.

Segment Analysis

By Product: Reagents Lead While Enzymes Accelerate

Kits & reagents contributed 65.52% of 2024 revenue, underlining their consumable nature in routine workflows. The enzymes portion, though smaller, is climbing at 12.25% CAGR as researchers demand ultra-high-fidelity polymerases for single-cell sequencing. DNA polymerases remain the dominant enzyme class, bolstered by a screening platform that can assay 10 million variants daily. Within the molecular biology enzymes, kits & reagents market size, Takara Bio’s mutant T7 RNA polymerase cuts double-stranded RNA by 90%, addressing mRNA-therapeutics quality needs.

Recurrence-driven revenue from PCR master mixes and NGS library kits cements reagent leadership. Yet enzymes capture premium pricing because single-amino-acid tweaks can halve error rates and improve CRISPR specificity. Machine-learning-aided evolution lets vendors tailor catalytic optima to new sequencing chemistries, ensuring double-digit growth for the enzymes slice of the molecular biology enzymes, kits & reagents market.

By Application: PCR Dominates As NGS Surges

PCR held 45.53% market share in 2024, reflecting ubiquity in diagnostics and QA. However, NGS is expanding at 16.53% CAGR on the back of falling per-genome costs and rapid oncology adoption. A new amplification method, AMPLON, shortens run time 50% without sacrificing accuracy, widening PCR’s reach into rapid screening.

CRISPR workflows are the fastest-growing niche inside the molecular biology enzymes, kits & reagents market, fueled by engineered Cas12a variants that deliver allele-specific edits. Epigenetics assays and protein-analysis kits also gain traction as multi-omic studies proliferate, creating cross-selling potential for integrated reagent bundles.

By End-User: Hospitals Lead While CROs Accelerate

Hospitals & diagnostic centers generated 45.82% of 2024 revenue thanks to mainstream use of molecular tests for infectious-disease panels and oncology markers. The CRO|CMO segment is growing at 13.26% CAGR as drug-development firms outsource specialized assays requiring bespoke reagent lots. Federal agencies estimate academic basic-research obligations grew in 2022, sustaining demand from universities.

Pharmaceutical innovators increasingly partner with CROs for single-cell RNA-seq and CRISPR screening, enlarging bulk-purchase contracts within the molecular biology enzymes, kits & reagents market. Forensic labs, meanwhile, adopt low-stutter STR kits such as Promega’s new enzyme formulation, ensuring stable if smaller-volume demand.

By Form: Liquid Dominates While Lyophilized Gains Ground

Liquid mixes accounted for 58.82% of 2024 sales owing to plug-and-play compatibility with automated platforms. Lyophilized products are rising at 14.62% CAGR because they travel at room temperature and cut cold-chain overhead. A colorimetric RT-LAMP kit retained full sensitivity after 28 days at ambient temperature.

Sustainability pressure encourages migration toward biobased plates and concentrated reagents that shrink plastic waste. Vendors in the molecular biology enzymes, kits & reagents industry now bundle lyophilized pellets with low-profile eco-friendly consumables to win procurement points under green-lab guidelines.

Geography Analysis

North America held 38.82% of 2024 revenue, anchored by NIH and NSF funding lines that sustain reagent consumption across academic and clinical labs. Strong reimbursement for molecular tests, despite MolDX hurdles, keeps hospital throughput high, and U.S. start-ups continue to spin out novel enzymes, maintaining regional leadership.

Europe posted steady mid-single-digit growth. Regulatory alignment under IVDR is driving demand for validated kit components, benefiting suppliers able to document performance to CE-IVD standards. Investment in antimicrobial-resistance surveillance has led to rollout of high-density qPCR systems capable of thousands of reactions per run, spurring reagent pull-through.

Asia-Pacific registers the fastest trajectory at 11.32% CAGR. China recorded a 35.84% jump in drug and device filings in 2023, with IVD reagents comprising nearly one-quarter of submissions. Japan is revising laboratory-developed-test frameworks, giving clarity to local innovators. South Korea’s tiered approval pathway expedites low-risk molecular assays, widening market access. APAC public-health agencies also invest in field-deployable diagnostics for rural clinics, accelerating uptake of lyophilized formats within the molecular biology enzymes, kits & reagents market size.

The Middle East & Africa are smaller today but pursue national genomics programs that mandate kit localization, signaling long-run upside. Latin America sees procurement spikes tied to disease-surveillance campaigns, though currency volatility moderates spending cycles.

Growth Rate — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The market is moderately fragmented. Thermo Fisher Scientific, Illumina, and Roche collectively deploy multibillion-dollar M&A war chests to assemble end-to-end workflows; Thermo Fisher alone targets USD 40–50 billion in future acquisitions. Bio-Rad seeks to close its Stilla Technologies purchase to round out digital PCR capabilities.

Mid-tier players such as New England Biolabs and Promega focus on proprietary enzyme engineering and sustainability-oriented consumables. Start-ups leverage AI-driven protein design to shorten R&D cycles, drawing venture funds toward niche CRISPR editing enzymes or synthetic-biology toolkits. Intellectual-property cross-licensing remains a gating factor; vendors with broad patent portfolios can bundle freedom-to-operate assurances into contracts, tipping competitive bids.

White-space opportunities include ultra-stable polymerases for microfluidic NGS, single-use plastics derived from renewable feedstocks, and automation-ready lyophilized mastermixes. The race to commercialize enzymatic DNA synthesis is another potential disruptor, as lower-cost gene assembly would further expand applications and pull reagent demand.

Molecular Biology Enzymes, Kits And Reagents Industry Leaders

Agilent Technologies
F. Hoffmann-La Roche Ltd
Merck KGaA
Qiagen NV
Thermo Fisher Scientific
*Disclaimer: Major Players sorted in no particular order

Molecular Biology Enzymes Kits And Reagents Market Concentration — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Need More Details on Market Players and Competitors?

Download PDF

Recent Industry Developments

April 2025: BioSkryb Genomics and Tecan launched a single-cell multi-omics workflow delivering sequencing-ready libraries in under 10 hours for cancer research.
February 2025: Bio-Rad issued a binding offer to acquire Stilla Technologies, a next-generation digital PCR specialist, with closing expected in Q3 2025.

Table of Contents for Molecular Biology Enzymes, Kits And Reagents Industry Report

1. Introduction

1.1 Study Assumptions & Market Definition
1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Rising Incidence Of Infectious Diseases & Genetic Disorders
- 4.2.2 Expanding Life-Science R&D Budgets
- 4.2.3 Rapid Advances In NGS, Qpcr & Dpcr Platforms
- 4.2.4 Growing Adoption Of Precision-Medicine Diagnostics
- 4.2.5 Ultra-High-Fidelity Enzymes Enabling Single-Cell Multi-Omics
- 4.2.6 Field-Deployable Lyophilized Kits Reduce Cold-Chain Costs
4.3 Market Restraints
- 4.3.1 High Cost & Limited Reimbursement For Genetic Testing
- 4.3.2 Complex IP & Licensing Landscape For Enzyme Patents
- 4.3.3 Fragile Supply Chain For Specialty Recombinant Reagents
- 4.3.4 Sustainability Pressure On Single-Use Kit Plastics
4.4 Porter's Five Forces
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitutes
- 4.4.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

5.1 By Product
- 5.1.1 Enzymes
- 5.1.1.1 DNA Polymerases
- 5.1.1.2 Reverse Transcriptases
- 5.1.1.3 Ligases & Kinases
- 5.1.1.4 Nucleases & Restriction Enzymes
- 5.1.1.5 Modifying Enzymes
- 5.1.1.6 Other Specialty Enzymes
- 5.1.2 Kits & Reagents
- 5.1.2.1 PCR Master-Mix & qPCR Kits
- 5.1.2.2 NGS/Library-Prep Kits
- 5.1.2.3 DNA/RNA Extraction & Purification Kits
- 5.1.2.4 Lyophilized Field-Use Kits
- 5.1.2.5 Buffers, dNTPs & Additives
5.2 By Application
- 5.2.1 Polymerase Chain Reaction
- 5.2.2 Next-Generation Sequencing
- 5.2.3 Epigenetics
- 5.2.4 Cloning & Synthetic Biology
- 5.2.5 Gene-Editing / CRISPR Workflows
- 5.2.6 Protein Analysis & Proteomics
5.3 By End-User
- 5.3.1 Hospitals & Diagnostic Centers
- 5.3.2 Academic & Research Institutes
- 5.3.3 Pharmaceutical & Biotechnology Companies
- 5.3.4 Contract Research & Manufacturing Organizations
- 5.3.5 Forensic & Security Laboratories
- 5.3.6 Food, Environmental & Agricultural Testing Labs
5.4 By Form
- 5.4.1 Liquid (Cold-Chain)
- 5.4.2 Lyophilized (Ambient)
5.5 Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 South Korea
- 5.5.3.5 Australia
- 5.5.3.6 Rest of Asia-Pacific
- 5.5.4 Middle East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America

6. Competitive Landscape

6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
- 6.3.1 Agilent Technologies
- 6.3.2 Thermo Fisher Scientific
- 6.3.3 F. Hoffmann-La Roche
- 6.3.4 Illumina
- 6.3.5 Merck KGaA (Sigma-Aldrich)
- 6.3.6 Qiagen
- 6.3.7 Takara Bio
- 6.3.8 New England Biolabs
- 6.3.9 Promega
- 6.3.10 Lucigen (LGC Biosearch)
- 6.3.11 Bio-Rad Laboratories
- 6.3.12 PerkinElmer
- 6.3.13 Oxford Nanopore Technologies
- 6.3.14 Pacific Biosciences
- 6.3.15 BGI Group
- 6.3.16 Bio-Techne
- 6.3.17 Enzymatics (Cell Signaling Tech)
- 6.3.18 Genscript
- 6.3.19 ArcherDx (Invitae)

7. Market Opportunities & Future Outlook

7.1 White-space & Unmet-Need Assessment

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections

Get Price Break-up Now

Global Molecular Biology Enzymes, Kits And Reagents Market Report Scope

As per the scope of the report, molecular biology enzymes, kits, and reagents are used for the analysis of cell surface markers that act as diagnostic and/or therapeutic targets. Molecular biology enzymes are natural proteins produced by living organisms (animals, plants, and bacteria) and are highly selective biochemical catalysts. Molecular biology reagents are chemicals used in molecular biology reactions to optimize workflow. The Molecular Biology Enzymes, Kits, and Reagents Market is segmented by Products (Enzymes, Kits, and Reagents), Application (Polymerase Chain Reaction, Sequencing, Epigenetics, and Other Applications), End-User (Hospitals and Diagnostic Centers, Academic and Research Institutes and Pharmaceutical and Biotechnology Companies) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product	Enzymes	DNA Polymerases
		Reverse Transcriptases
		Ligases & Kinases
		Nucleases & Restriction Enzymes
		Modifying Enzymes
		Other Specialty Enzymes

	Kits & Reagents	PCR Master-Mix & qPCR Kits
		NGS/Library-Prep Kits
		DNA/RNA Extraction & Purification Kits
		Lyophilized Field-Use Kits
		Buffers, dNTPs & Additives
By Application	Polymerase Chain Reaction
	Next-Generation Sequencing
	Epigenetics
	Cloning & Synthetic Biology
	Gene-Editing / CRISPR Workflows
	Protein Analysis & Proteomics
By End-User	Hospitals & Diagnostic Centers
	Academic & Research Institutes
	Pharmaceutical & Biotechnology Companies
	Contract Research & Manufacturing Organizations
	Forensic & Security Laboratories
	Food, Environmental & Agricultural Testing Labs
By Form	Liquid (Cold-Chain)
	Lyophilized (Ambient)

Geography	North America	United States
		Canada
		Mexico

	Europe	Germany
		United Kingdom
		France
		Italy
		Spain
		Rest of Europe

	Asia-Pacific	China
		Japan
		India
		South Korea
		Australia
		Rest of Asia-Pacific

	Middle East and Africa	GCC
		South Africa
		Rest of Middle East and Africa

	South America	Brazil
		Argentina
		Rest of South America

By Product

Enzymes	DNA Polymerases
	Reverse Transcriptases
	Ligases & Kinases
	Nucleases & Restriction Enzymes
	Modifying Enzymes
	Other Specialty Enzymes
Kits & Reagents	PCR Master-Mix & qPCR Kits
	NGS/Library-Prep Kits
	DNA/RNA Extraction & Purification Kits
	Lyophilized Field-Use Kits
	Buffers, dNTPs & Additives

By Application

Polymerase Chain Reaction

Next-Generation Sequencing

Epigenetics

Cloning & Synthetic Biology

Gene-Editing / CRISPR Workflows

Protein Analysis & Proteomics

By End-User

Hospitals & Diagnostic Centers

Academic & Research Institutes

Pharmaceutical & Biotechnology Companies

Contract Research & Manufacturing Organizations

Forensic & Security Laboratories

Food, Environmental & Agricultural Testing Labs

By Form

Liquid (Cold-Chain)

Lyophilized (Ambient)

Geography

North America	United States
	Canada
	Mexico
Europe	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe
Asia-Pacific	China
	Japan
	India
	South Korea
	Australia
	Rest of Asia-Pacific
Middle East and Africa	GCC
	South Africa
	Rest of Middle East and Africa
South America	Brazil
	Argentina
	Rest of South America

Need A Different Region or Segment?

Customize Now

Key Questions Answered in the Report

What is the current size of the molecular biology enzymes, kits & reagents market?

The molecular biology enzymes, kits & reagents market size stands at USD 13.68 billion in 2025, with a projected value of USD 22.53 billion by 2030.

Which segment is expanding the fastest?

Enzymes are the quickest-growing product segment, advancing at a 12.25% CAGR due to demand for ultra-high-fidelity polymerases and CRISPR-specific nucleases.

Why are lyophilized kits gaining popularity?

Lyophilized formulations enable room-temperature shipping and storage, lowering cold-chain costs and supporting field diagnostics where infrastructure is limited.

How do reimbursement policies affect market growth?

Restrictive coverage criteria under programs such as Medicare MolDX can delay adoption of innovative tests, trimming projected CAGR by an estimated 1.6%.

Which geographic region offers the highest growth potential?

Asia-Pacific shows the highest CAGR at 11.32% through 2030, fueled by rising R&D investments, regulatory reforms, and expanding precision-medicine programs.